Catalyst Pharmaceutical CPRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $63.73M+20.9% | $52.7M-0.2% | $52.78M+1.3% | $52.11M-8.2% | $56.74M+1.4% | ||
| $70K-2.8% | $72K0.0% | $72K-37.9% | $116K+0.9% | $115K+0.9% | ||
| $6.26M+10.6% | $5.66M-0.2% | $5.67M-25.4% | $7.6M+29.9% | $5.85M+13.1% | ||
| $2.34M-48.2% | $4.51M— | —— | $2.43M+4.9% | $2.32M— | ||
| $4.36M-78.3% | $20.07M-50.5% | $40.55M— | $0-100% | $5.79M-19.7% | ||
| -$2.24M-124% | $9.22M+1.5% | $9.09M+2,097% | -$455K-292% | $237K— | ||
| -$4.05M— | —— | —— | -$5.67M-5.1% | -$5.4M-207% | ||
| -$9.21M-277% | $5.21M-60.7% | $13.24M+60.2% | $8.27M+424% | -$2.55M-129% | ||
| -$2.45M— | —— | $6.7M-9.6% | $7.41M+206% | -$7.02M-364% | ||
| $9.7M+2.5% | $9.47M+1.3% | $9.34M0.0% | $9.34M0.0% | $9.35M0.0% | ||
| $4.75M+41.0% | $3.37M+261% | -$2.09M+29.2% | -$2.95M-212% | $2.64M-60.7% | ||
| -$106K-3.9% | -$102K0.0% | -$102K-2.0% | -$100K-3.1% | -$97K-3.2% | ||
| $59.59M+32.7% | $44.89M+38.4% | $32.44M-54.5% | $71.3M+18.7% | $60.04M-15.3% | ||
| $27K-15.6% | $32K— | $0-100% | $26K— | $0-100% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$27K+15.6% | -$32K— | $0+100% | -$26K— | -$0+100% | ||
| $14.57M+130% | $6.33M0.0% | $6.33M0.0% | $6.33M0.0% | $6.33M— | ||
| $3.3M— | $0— | $0— | $0— | $0— | ||
| $301K-67.0% | $912K— | $0-100% | $219K-65.9% | $642K+38.4% | ||
| -$12.87M+49.7% | -$25.58M-650% | $4.65M+434% | $872K-71.5% | $3.06M-31.0% | ||
| $46.69M+142% | $19.28M-48.0% | $37.09M-48.6% | $72.14M+14.3% | $63.1M-16.1% | ||
| $140K+7.7% | $130K+7.4% | $121K+8.0% | $112K+8.7% | $103K+9.6% | ||
| $1.84M-89.1% | $16.85M+6.0% | $15.9M-58.8% | $38.6M+5,941% | $639K-96.2% | ||
| $135K+16.4% | $116K+20.8% | $96K+23.1% | $78K+30.0% | $60K+53.8% | ||
| $9.7M+2.5% | $9.47M+1.3% | $9.34M0.0% | $9.34M0.0% | $9.35M0.0% | ||
| $70K-2.8% | $72K0.0% | $72K-37.9% | $116K+0.9% | $115K+0.9% | ||
| $4.75M+41.0% | $3.37M+261% | -$2.09M+29.2% | -$2.95M-212% | $2.64M-60.7% | ||
| -$9.21M-277% | $5.21M-60.7% | $13.24M+60.2% | $8.27M+424% | -$2.55M-129% | ||
| $2.34M-48.2% | $4.51M— | —— | $2.43M+4.9% | $2.32M— | ||
| -$106K-3.9% | -$102K0.0% | -$102K-2.0% | -$100K-3.1% | -$97K-3.2% | ||
| -$2.45M— | —— | $6.7M-9.6% | $7.41M+206% | -$7.02M-364% | ||
| $77K+2.7% | $75K+1.4% | $74K0.0% | $74K+2.8% | $72K+1.4% | ||
| $1.3M+4.4% | $1.24M+8.9% | $1.14M+2.1% | $1.12M+3.1% | $1.09M-0.2% | ||
| —— | $3.13M0.0% | $3.13M0.0% | $3.13M0.0% | $3.13M— | ||
| -$106K-3.9% | -$102K0.0% | -$102K-2.0% | -$100K-3.1% | -$97K-3.2% | ||
| $59.56M+32.8% | $44.86M+38.3% | $32.44M-54.5% | $71.27M+18.7% | $60.04M-15.2% | ||
| $59.56M+32.8% | $44.86M+38.3% | $32.44M-54.5% | $71.27M+18.7% | $60.04M-15.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Catalyst Pharmaceutical's cash flow data come from?
- Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.